EU marketing authorisation under exceptional circumstances

Reviewed by the Reserve Meds clinical operations team on 17 October 2026. Sources accessed 17 October 2026.

What exceptional circumstances means

EMA defines it as a type of marketing authorisation granted to medicines where the applicant is unable to provide comprehensive data on efficacy and safety under normal conditions of use, because the condition to be treated is rare, or because collecting full information is not possible or is unethical.^[1]

This route is most relevant to very rare diseases, where there may never be enough patients for the size of trial normally expected.

How it differs from a conditional marketing authorisation

With a conditional marketing authorisation, approval is granted on the expectation that the company will provide comprehensive data within an agreed timeframe. With exceptional circumstances, EMA authorises the medicine when comprehensive data cannot be obtained even after authorisation, and EMA notes that this route normally does not lead to a standard marketing authorisation.^[2]

In both cases, the medicine is approved in the EU. The difference is what evidence is expected after approval and how the authorisation is reviewed over time.

What families should look for

The European public assessment report and product information describe the evidence and any conditions attached. A treating specialist can explain what the data cover and what is still unknown, which matters most in rare diseases with small studies.

If the same medicine is also approved by the US FDA, the US label is the reference we use when coordinating access. FDA approvals for rare diseases may come with their own conditions, such as accelerated approval.^[3]

What it means for patients in the Gulf

Why this matters in the Gulf: Saudi Arabia's SFDA runs reliance pathways that build on decisions by other regulators. Its performance target is 30 working days for the verification pathway, which needs approval and marketing by both the US FDA and the EMA, and 60 working days for the abridged pathway, which needs one of them. The manufacturer still has to apply; nothing happens automatically.^[4]

Until a medicine is registered locally, a patient in the Gulf usually reaches an FDA-approved medicine through a hospital request to the national regulator, such as the SFDA Special Access Program in Saudi Arabia or the procedure in NHRA Circular 41 of 2020 in Bahrain.^{[5, 6]}

Questions to ask the treating specialist

• How many patients were studied before approval, and what is still unknown?
• Is there a patient registry or follow-up the company or regulator expects us to join?
• Is the medicine approved by the US FDA too, and are the indications the same?
• If it is not registered here, will the hospital request it for my child or relative?

How regulators abroad treat EU approvals

Some Gulf regulators accept an EU approval as a reference when a hospital asks to import an unregistered medicine. Bahrain's NHRA Circular 41 of 2020, for example, lists the EMA or a Western European country among the reference regulators, alongside the US FDA.^[6]

How Reserve Meds helps

Reserve Meds is a digital health company. Medicines are supplied through a US-licensed pharmaceutical wholesale partner. We help families and treating doctors understand the route, prepare the documents the regulator or hospital asks for, arrange supply from the US once approval is in place, and keep everyone updated. We do not diagnose, prescribe or decide what a regulator approves.

We coordinate access to FDA-approved medicines only. Investigational medicines are only available through a manufacturer's expanded-access program requested by the treating physician; we can explain that route, but we do not supply them. Your coordination fee is quoted in writing for your case before you commit. No hidden charges. We give you a written timeline estimate for your case before you commit.

Sources for these answers: ^{[1, 2, 5]}

Related

• EU conditional marketing authorisation
• Orphan drug designation
• All access pathways
• US expanded access (compassionate use)
• Named-patient access, explained
• Answers to common access questions

This page is general information, not medical or legal advice. It does not replace advice from your own doctor or the regulator.